{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T08:30:56Z","timestamp":1770971456335,"version":"3.50.1"},"reference-count":38,"publisher":"Frontiers Media SA","content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2017.01103","type":"journal-article","created":{"date-parts":[[2018,2,15]],"date-time":"2018-02-15T12:29:19Z","timestamp":1518697759000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":45,"title":["Prolonged Excretion of Poliovirus among Individuals with Primary Immunodeficiency Disorder: An Analysis of the World Health Organization Registry"],"prefix":"10.3389","volume":"8","author":[{"given":"Grace","family":"Macklin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Liao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"Takane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathleen","family":"Dooling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stuart","family":"Gilmour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ondrej","family":"Mach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olen M.","family":"Kew","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roland W.","family":"Sutter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"The iVDPV Working Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2017,9,25]]},"reference":[{"key":"B1","volume-title":"Acute Flaccid Paralysis (AFP) Surveillance Data and Polio Case Count","year":"2017"},{"key":"B2","first-page":"222","article-title":"Apparent global interruption of wild poliovirus type 2 transmission","volume":"50","year":"2001","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"B3","first-page":"1031","article-title":"Possible eradication of wild poliovirus type 3 \u2013 worldwide, 2012","volume":"63","author":"Kew","year":"2014","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"B4","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1146\/annurev.micro.58.030603.123625","article-title":"Vaccine-derived polioviruses and the endgame strategy for global polio eradication","volume":"59","author":"Kew","year":"2005","journal-title":"Annu Rev Microbiol"},{"key":"B5","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/B978-1-4557-0090-5.00035-5","article-title":"Poliovirus vaccine \u2013 live","volume-title":"Vaccines","author":"Sutter","year":"2013"},{"key":"B6","first-page":"16","article-title":"Circulating vaccine-derived polioviruses: current state of knowledge","volume":"82","author":"Kew","year":"2004","journal-title":"Bull World Health Organ"},{"key":"B7","doi-asserted-by":"publisher","first-page":"S176","DOI":"10.1093\/infdis\/175.Supplement_1.S176","article-title":"Duration of poliovirus excretion and its implications for acute flaccid paralysis surveillance: a review of the literature","volume":"175","author":"Alexander","year":"1997","journal-title":"J Infect Dis"},{"key":"B8","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.biologicals.2006.02.005","article-title":"Vaccine-derived poliovirus from long term excretors and the end game of polio eradication","volume":"34","author":"Martin","year":"2006","journal-title":"Biologicals"},{"key":"B9","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1128\/JCM.36.10.2893-2899.1998","article-title":"Prolonged replication of a type 1 vaccine-derived poliovirus in an immunodeficient patient","volume":"36","author":"Kew","year":"1998","journal-title":"J Clin Microbiol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"3001","DOI":"10.1128\/JVI.74.7.3001-3010.2000","article-title":"Evolution of the Sabin strain of type 3 poliovirus in an immunodeficient patient during the entire 637-day period of virus excretion","volume":"74","author":"Mart\u00edn","year":"2000","journal-title":"J Virol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1006\/viro.1999.0003","article-title":"Evolution of poliovirus type I during 5.5 years of prolonged enteral replication in an immunodeficient patient","volume":"265","author":"Bellmunt","year":"1999","journal-title":"Virology"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1099\/vir.0.18974-0","article-title":"Nucleotide variation in Sabin type 2 poliovirus from an immunodeficient patient with poliomyelitis","volume":"84","author":"Buttinelli","year":"2003","journal-title":"J Gen Virol"},{"key":"B13","volume-title":"Polio Eradication & Endgame Strategic Plan 2013-2018","year":"2013"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1111\/j.1539-6924.2006.00827.x","article-title":"Risks of paralytic disease due to wild or vaccine-derived poliovirus after eradication","volume":"26","author":"Tebbens","year":"2006","journal-title":"Risk Anal"},{"key":"B15","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1186\/s12879-015-1115-5","article-title":"Modeling the prevalence of immunodeficiency-associated long-term vaccine-derived poliovirus excretors and the potential benefits of antiviral drugs","volume":"15","author":"Duintjer Tebbens","year":"2015","journal-title":"BMC Infect Dis"},{"key":"B16","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1017\/S0950268816002302","article-title":"Comprehensive screening for immunodeficiency-associated vaccine-derived poliovirus: an essential oral poliovirus vaccine cessation risk management strategy","volume":"145","author":"Duintjer Tebbens","year":"2017","journal-title":"Epidemiol Infect"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1016\/j.vaccine.2015.01.018","article-title":"Immunodeficiency-related vaccine-derived poliovirus (iVDPV) cases: a systematic review and implications for polio eradication","volume":"33","author":"Guo","year":"2015","journal-title":"Vaccine"},{"key":"B18","doi-asserted-by":"publisher","first-page":"S368","DOI":"10.1093\/infdis\/jiu065","article-title":"Poliovirus excretion among persons with primary immune deficiency disorders: summary of a seven-country study series","volume":"210","author":"Li","year":"2014","journal-title":"J Infect Dis"},{"key":"B19","doi-asserted-by":"publisher","first-page":"7561","DOI":"10.1016\/j.vaccine.2012.10.035","article-title":"Prevalence of prolonged and chronic poliovirus excretion among persons with primary immune deficiency disorders in Sri Lanka","volume":"30","author":"de Silva","year":"2012","journal-title":"Vaccine"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1128\/CVI.00293-12","article-title":"High susceptibility for enterovirus infection and virus excretion features in Tunisian patients with primary immunodeficiencies","volume":"19","author":"Driss","year":"2012","journal-title":"Clin Vaccine Immunol"},{"key":"B21","volume-title":"Polio Laboratory Manual","year":"2004"},{"key":"B22","doi-asserted-by":"publisher","first-page":"4429","DOI":"10.1128\/JVI.02354-07","article-title":"Calibration of multiple poliovirus molecular clocks covering an extended evolutionary range","volume":"82","author":"Jorba","year":"2008","journal-title":"J Virol"},{"key":"B23","first-page":"358","article-title":"Update on vaccine-derived polioviruses detected worldwide, April 2011\u2013June 2012","volume":"87","year":"2012","journal-title":"Wkly Epidemiol Rec"},{"key":"B24","unstructured":"Country and Lending Groups2016"},{"key":"B25","volume-title":"R: A Language and Environment for Statistical Computing","author":"Core Team","year":"2016"},{"key":"B26","volume-title":"Stata Statistical Software: Release 13","year":"2013"},{"key":"B27","doi-asserted-by":"publisher","first-page":"e1005114","DOI":"10.1371\/journal.ppat.1005114","article-title":"Twenty-eight years of poliovirus replication in an immunodeficient individual: impact on the global polio eradication initiative","volume":"11","author":"Dunn","year":"2015","journal-title":"PLoS Pathog"},{"key":"B28","volume-title":"WHO\u2013Recommended Standards for Surveillance of Selected Vaccine-Preventable Diseases","year":"2003"},{"key":"B29","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1111\/j.1600-0897.2006.00409.x","article-title":"Consanguinity in primary immunodeficiency disorders; the report from Iranian Primary Immunodeficiency Registry","volume":"56","author":"Rezaei","year":"2006","journal-title":"Am J Reprod Immunol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1000331","DOI":"10.4172\/2157-7560.1000331","article-title":"Poliovirus excretion among persons with primary immune deficiency disorders: summary of data from enhanced poliovirus surveillance in Egypt, 2011\u20132014","volume":"7","author":"El-Sayed","year":"2016","journal-title":"J Vaccines Vaccin"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.3201\/eid2210.151071","article-title":"Vaccine-derived polioviruses and children with primary immunodeficiency, Iran, 1995-2014","volume":"22","author":"Shaghaghi","year":"2016","journal-title":"Emerg Infect Dis"},{"key":"B32","doi-asserted-by":"publisher","first-page":"934","DOI":"10.15585\/mmwr.mm6535a3","article-title":"Cessation of trivalent oral poliovirus vaccine and introduction of inactivated poliovirus vaccine \u2013 worldwide, 2016","volume":"65","author":"Hampton","year":"2016","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"B33","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1007\/s10875-007-9075-1","article-title":"Long-term follow-up and outcome of a large cohort of patients with common variable immunodeficiency","volume":"27","author":"Quinti","year":"2007","journal-title":"J Clin Immunol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1126\/science.311.5767.1539a","article-title":"Infectious diseases. Report concludes polio drugs are needed \u2013 after disease is eradicated","volume":"311","author":"Couzin","year":"2006","journal-title":"Science"},{"key":"B35","first-page":"335","article-title":"Antiviral activity of pocapavir in a randomized, blinded, placebo-controlled human oral poliovirus vaccine challenge model","volume":"215","author":"Collett","year":"2017","journal-title":"J Infect Dis"},{"key":"B36","doi-asserted-by":"publisher","first-page":"S447","DOI":"10.1093\/infdis\/jiu043","article-title":"Progress in the development of poliovirus antiviral agents and their essential role in reducing risks that threaten eradication","volume":"210","author":"McKinlay","year":"2014","journal-title":"J Infect Dis"},{"key":"B37","unstructured":"10 Warning Signs of Primary Immunodeficiency2017"},{"key":"B38","volume-title":"12th Meeting of the SAGE Polio Working Group","year":"2016"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fimmu.2017.01103\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,28]],"date-time":"2020-10-28T05:22:57Z","timestamp":1603862577000},"score":1,"resource":{"primary":{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fimmu.2017.01103\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,25]]},"references-count":38,"alternative-id":["10.3389\/fimmu.2017.01103"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2017.01103","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,25]]},"article-number":"1103"}}